EP4719421A1 — Combination therapy comprising kit inhibitors for use in the treatment of cancer
Assigned to IDRx Inc · Expires 2026-04-08 · 0y expired
What this patent protects
The present disclosure relates to methods and compositions for treating conditions associated with aberrant KIT activity ( e.g. , cancer). The methods and compositions described herein generally comprise a compound of Formula (I) and M4205 or THE-630.
USPTO Abstract
The present disclosure relates to methods and compositions for treating conditions associated with aberrant KIT activity ( e.g. , cancer). The methods and compositions described herein generally comprise a compound of Formula (I) and M4205 or THE-630.
Drugs covered by this patent
- Ayvakit (AVAPRITINIB) · Blueprint Medicines
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.